Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $125.00 short put and a strike $120.00 long put offers a potential 19.05% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $125.00 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $4.20 would be incurred if the stock dropped below the $120.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 74.53 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Lilly's Emgality Gets FDA Priority Review for Cluster Headache
Wed, 06 Mar 2019 16:34:04 +0000
Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
FDA Approves Major Novel Depression Drug For First Time In 3 Decades
Wed, 06 Mar 2019 14:25:43 +0000
Johnson & Johnson (NYSE: JNJ)'s Janssen unit announced Tuesday that the FDA approved Spravato — chemically esketamine CIII nasal spray — for use in conjunction with an oral antidepressant in adults with treatment-resistant depression. A patient is said to be afflicted with treatment-resistant depression if they have tried at least two antidepressants but not benefited from them.
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression
Wed, 06 Mar 2019 13:50:01 +0000
J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
3 Big Pharmas Trying to Pop the Rebate Bubble
Wed, 06 Mar 2019 13:16:00 +0000
Pharmaceutical companies are suddenly eager to lower drug prices.
See what the IHS Markit Score report has to say about Eli Lilly and Co.
Wed, 06 Mar 2019 13:00:37 +0000
Eli Lilly and Co NYSE:LLYView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for LLY with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 4. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding LLY are favorable, with net inflows of $10.71 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. LLY credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Also on Market Tamer…
Follow Us on Facebook